Grow Pharma CEO sees an opportunity for medical cannabis after Brexit


Imports and exports have changed since Brexit – including drug trade between the EU and the UK. Pierre Van Weperen, CEO of Grow Pharma, talks to Proactive London about how the company’s partner, IPS Pharma, will manufacture the cannabis oils in its certified production facility in Surrey.

Not only will this solve import and export problems at the borders between the EU and the UK, but it will also save money. According to Grow Pharma, attempts have been made to extract cannabis-based medical devices in the UK. This makes it the second company after GW Pharmaceuticals (NASDAQ: GWPH) to do so. Privately owned distributor Grow, part of, said it is trying to replicate and distribute cannabis-based medicines (CBMPs) for patients experiencing a disruption of supply due to Brexit.